Archived explainer. For the current picture see today's BHVN page.
Why Is BIOHAVEN LTD (BHVN) Stock Up Today?
BIOHAVEN LTD (BHVN) is up +7.52% in the latest session. Our newswire has captured 4 stories on BHVN across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 69/100).
Biohaven Ltd (BHVN) shares rose 7.52% to $13.87, driven by the presentation of promising Phase 1 clinical data for its experimental drug BHV-1530. The move was further supported by an analyst price target increase from JPMorgan, which raised its target to $35 from $14.
What Happened
Biohaven announced that its novel FGFR3-directed antibody-drug conjugate, BHV-1530, demonstrated clinical activity and confirmed responses in patients with FGFR3-altered urothelial and head and neck cancers. The data was presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. The company highlighted deep and durable responses in the treated patient population, marking a significant milestone for the program.
In addition to the clinical update, JPMorgan increased its price target for the stock to $35, citing the positive clinical readout. This analyst action coincided with the market reaction to the conference presentation. The stock had previously declined 15.3% over the preceding eight sessions, falling from $15.23 to $12.90, making the recent rebound notable against the short-term downtrend.
What The Data Shows
The stock opened at $13.03, a 1.0% gap from the prior close of $12.90, and reached a session high of $14.04 at 9:55 AM ET. Trading volume totaled 0.3 million shares, which is 0.1 times the three-month daily average. The intraday low was $12.85 at 7:30 AM ET.
Biohaven remains unprofitable with a trailing twelve-month earnings per share of -$3.81 and a market capitalization of $2.0 billion. The stock has a beta of 3.13 and trades within a 52-week range of $8.03 to $18.24. On November 19, 2026, the stock printed nine fresh 52-week highs and one fresh 52-week low.
What To Watch
Market participants will monitor future clinical updates for BHV-1530 and the company’s Graves' disease program. Analyst coverage remains a key factor, with recent price target adjustments from JPMorgan, Morgan Stanley, and Deutsche Bank influencing sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
BHVN by the numbers
The headlines behind the move
Biohaven’s BHV-1530 shows clinical activity, confirmed responses in cancer study
Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell...
Biohaven price target raised to $35 from $14 at JPMorgan
More on BHVN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier BHVN move explainers: 2026-11-19 · 2026-10-23 · 2026-09-11 · 2026-09-10 · 2026-08-27 · 2026-08-26